Table 1 Comparison of properties of novel immune checkpoint modulators
From: Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Target | Chromosomal location | Binding partner | Expression |
|---|---|---|---|
VISTA | 10q22.1 | VSIG3 | Myeloid cells, T cells |
CD38 | 4p15.32 | CD31 | Non-hematopoietic cells, immune cells |
CD39 | 10q24.1 | Unknown | B cells, NK cells, DCs, monocytes, macrophages, Tregs |
CD73 | 6q14.3 | Unknown | endothelial cells, lymphocytes, tumor cells, stromal cells |
LAG-3 | 12p13.31 | MHC-II, galectin-3, LSECtin, a-synuclein, FGL1 | Activated T cells, B cells, Tregs, NK cells, DCs |
IDO-1 | 8p11.21 | AhR | DCs, eosinophils, tumor cells |
CD27 | 12p13.31 | CD70 | T cells, B cells, plasma cells, NK cells |
TIM-3 | 5q33.2 | Galectin-9, Ceacam-1, HMGB1, PtdSer | Activated T cells, B cells, Tregs, DCs, NK cells, monocytes |
CD47 | 3q13.12 | SIRPA | Human cells, tumor cells |
CD93 | 20p11.21 | IL-17D | Endothelial cells |
CD161 | 12p13.31 | LLT1 | NK cells, T cells |
BTLA | 3q13.2 | HVEM | Mature B cells, T cells, Tregs, macrophages, DCs |
VTCN1 | 1p13.1-p12 | Unknow | Antigen-presenting cells |
B7-H3 | 15q24.1 | Unknow | Activated T cells, NK cells, DCs, monocytes, tumor cells |
TIGIT | 3q13.31 | CD155, CD112, CD113 | NK cells, activated T cells, Tregs, follicular T helper cells |